Decoy Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Decoy Therapeutics Inc. (DCOY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.61% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-31
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.27%, a 151.18% increase year-over-year.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 1.70%.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.61%, a 0.00% change from fiscal 2024.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.61%.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 1.70%, a 55.96% increase from fiscal 2021.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.09%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.61% 10-K · filed 2026-03-31 | |||
| 2024-12-31 | 4.61% 10-K · filed 2025-03-21 | |||
| 2024-09-30 | 4.61% 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | 4.61% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 4.27% 10-Q · filed 2025-05-14 | |||
| 2023-09-30 | 1.70% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 1.70% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 1.70% 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 1.70% 10-K · filed 2024-03-22 | |||
| 2022-09-30 | 1.70% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 1.70% 10-Q · filed 2022-08-05 | |||
| 2021-12-31 | 1.09% 10-K · filed 2023-03-27 | |||
| 2021-09-30 | 1.00% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 1.00% 10-Q · filed 2022-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |